7
1
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T2277 | Losmapimod | GSK-AHAB,GW856553X,GW856553,SB856553 | p38 MAPK , Autophagy |
Losmapimod (GSK-AHAB) (GW856553X; SB856553; GSK-AHAB) is a specific, potent, and orally active p38 MAPK inhibitor (pKi: 8.1/7.6 for p38α/β). | |||
T13324 | VUF11207 fumarate | CXCR , Arrestin | |
VUF11207 fumarate is an agonist of CXCR7 and a high-potency ligand of CXCR7 (pKi: 8.1). | |||
T36084 | PKI-179 | ||
PKI-179 is a potent, orally active compound that functions as a dual PI3K/mTOR inhibitor. It demonstrates IC50 values of 8 nM for PI3K-α, 24 nM for PI3K-β, 74 nM for PI3K-γ, 77 nM for PI3K-δ, and 0.42 nM for mTOR. Additi... | |||
TP2096 | ELA-21 (human) | ||
High affinity apelin receptor agonist. Binds apelin receptors in left ventricle from normal and pulmonary arterial hypertensive (PAH) hearts (pKi values are 9.31 and 9.46, respectively). Bioactive fragment of ELA-32. Inh... | |||
T75989 | Malantide TFA | ||
Malantide TFA, a synthetic dodecapeptide, originates from the phosphorylation site targeted by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Exhibiting a high specificity for PKA with a Mi... | |||
T78691 | PI3Kδ-IN-12 | PI3K | |
PI3Kδ-IN-12 (compound 13), a PI3Kδ inhibitor with a pIC50 of 5.8, exhibits differential binding affinities with pKi values of 8.0 for PI3Kδ, 6.5 for PI3Kγ, 6.4 for PI3Kβ, and 6.7 for PI3Kα. This compound is utilized in r... | |||
T36085 | PKI-179 hydrochloride | ||
PKI-179 is an orally bioavailable dual inhibitor of PI3K and mammalian target of rapamycin (mTOR). In an in vitro enzymatic assay, it potently inhibits PI3K (IC50s = 8, 24, 17, and 74 nM for isoforms α, β, δ, and γ, resp... |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPJ-01309 | PKI-Beta Protein, Human, Recombinant (His) | Human | E. coli |
cAMP-Dependent Protein Kinase Inhibitor β (PKI-β) is a member of the PKI family. As a member of the cAMP-dependent protein kinase inhibitor family,It has been shown that PKI-β is an extremely potent competitive inhibitor... |